Mesoblast (MESO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MESO Stock Forecast

Mesoblast stock forecast is as follows: an average price target of $11.50 (represents a 12.97% upside from MESO’s last price of $10.18) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

MESO Price Target

The average price target for Mesoblast (MESO) is $11.50 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $11.00. This represents a potential 12.97% upside from MESO's last price of $10.18.

MESO Analyst Ratings

Buy

According to 11 Wall Street analysts, Mesoblast's rating consensus is 'Buy'. The analyst rating breakdown for MESO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 3 'Hold' (27.27%), 2 'Sell' (18.18%), and 0 'Strong Sell' (0.00%).

Mesoblast Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Jason McCarthy	Maxim Group	$12.00	$6.74	78.04%	17.88%
Jul 23, 2024	Edward Tenthoff	Piper Sandler	$11.00	$8.27	33.01%	8.06%

Row per page

Go to

The latest Mesoblast stock forecast, released on Sep 24, 2024 by Jason McCarthy from Maxim Group, set a price target of $12.00, which represents a 78.04% increase from the stock price at the time of the forecast ($6.74), and a 17.88% increase from MESO last price ($10.18).

Mesoblast Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$12.00	$11.50
Last Closing Price	$10.18	$10.18	$10.18
Upside/Downside	-100.00%	17.88%	12.97%

In the current month, the average price target of Mesoblast stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mesoblast's last price of $10.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 23, 2024	Piper Sandler	-	Overweight	Upgrade
Aug 31, 2023	Citigroup	Overweight	Overweight	Hold
Aug 31, 2023	Argus Research	-	Buy	Upgrade
Aug 31, 2023	Canaccord Genuity	-	Buy	Upgrade
Aug 31, 2023	BMO Capital	-	Outperform	Upgrade
Aug 31, 2023	Citigroup	-	Buy	Upgrade
Aug 31, 2023	Wells Fargo	-	Equal-Weight	Upgrade
Aug 31, 2023	Jefferies	Hold	Buy	Upgrade
Aug 31, 2023	Oppenheimer	-	Perform	Downgrade
Aug 31, 2023	Susquehanna	-	Negative	Downgrade

Row per page

Go to

Mesoblast's last stock rating was published by Piper Sandler on Jul 23, 2024. The company Upgrade its MESO rating from "null" to "Overweight".

Mesoblast Financial Forecast

Mesoblast Revenue Forecast

	Jun 30	Mar 30	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.94M	$1.98M	$1.44M
Avg Forecast	$19.59M	$16.34M	$4.10M	$3.87M	$3.87M	$2.14M	$2.10M	$3.47M	$7.59M	$2.10M	$3.50M	$2.35M	$17.71M	$29.20M	$15.63M	$40.58M	$12.71M	$9.05M	$4.13M	$2.09M	$2.09M	$1.52M	$4.08M	$3.81M	$6.84M	$5.60M	$2.38M	$2.14M	$2.10M	$3.47M
High Forecast	$19.59M	$16.34M	$4.10M	$3.87M	$3.87M	$2.14M	$2.10M	$3.47M	$7.59M	$2.10M	$3.50M	$2.35M	$17.71M	$29.20M	$15.63M	$40.58M	$12.71M	$9.05M	$4.13M	$2.09M	$2.09M	$1.52M	$4.09M	$3.81M	$6.84M	$5.60M	$2.38M	$2.14M	$2.10M	$3.47M
Low Forecast	$19.59M	$16.34M	$4.10M	$3.87M	$3.87M	$2.14M	$2.10M	$3.47M	$7.59M	$2.10M	$3.50M	$2.35M	$17.71M	$29.20M	$15.63M	$40.58M	$12.71M	$9.05M	$4.13M	$2.09M	$2.09M	$1.52M	$4.07M	$3.81M	$6.84M	$5.60M	$2.38M	$2.14M	$2.10M	$3.47M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.94%	0.42%

Mesoblast's average Quarter revenue forecast for Jun 23 based on 1 analysts is $2.38M, with a low forecast of $2.38M, and a high forecast of $2.38M. MESO's average Quarter revenue forecast represents a 22.92% increase compared to the company's last Quarter revenue of $1.94M (Mar 23).

Mesoblast EBITDA Forecast

	Jun 30	Mar 30	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-13.47M	$-20.03M	$-14.90M
Avg Forecast	$-19.59M	$-16.34M	$-4.10M	$-3.87M	$-3.87M	$-2.14M	$-2.10M	$-3.47M	$-7.59M	$-2.10M	$-3.50M	$-2.35M	$-17.71M	$-29.20M	$-15.63M	$-40.58M	$-12.71M	$-9.05M	$-4.13M	$-2.09M	$-2.09M	$-1.52M	$-4.08M	$-3.81M	$-6.84M	$-5.60M	$-2.38M	$-2.14M	$-2.10M	$-3.47M
High Forecast	$-19.59M	$-16.34M	$-4.10M	$-3.87M	$-3.87M	$-2.14M	$-2.10M	$-3.47M	$-7.59M	$-2.10M	$-3.50M	$-2.35M	$-17.71M	$-29.20M	$-15.63M	$-40.58M	$-12.71M	$-9.05M	$-4.13M	$-2.09M	$-2.09M	$-1.52M	$-4.07M	$-3.81M	$-6.84M	$-5.60M	$-2.38M	$-2.14M	$-2.10M	$-3.47M
Low Forecast	$-19.59M	$-16.34M	$-4.10M	$-3.87M	$-3.87M	$-2.14M	$-2.10M	$-3.47M	$-7.59M	$-2.10M	$-3.50M	$-2.35M	$-17.71M	$-29.20M	$-15.63M	$-40.58M	$-12.71M	$-9.05M	$-4.13M	$-2.09M	$-2.09M	$-1.52M	$-4.09M	$-3.81M	$-6.84M	$-5.60M	$-2.38M	$-2.14M	$-2.10M	$-3.47M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.30%	9.54%	4.30%

undefined analysts predict MESO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mesoblast's previous annual EBITDA (undefined) of $NaN.

Mesoblast Net Income Forecast

	Jun 30	Mar 30	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-18.60M	$-24.49M	$-16.88M
Avg Forecast	$-250.33M	$-253.31M	$-300.57M	$-363.15M	$-363.15M	$-268.02M	$-226.05M	$-263.72M	$-165.50M	$-217.97M	$-328.31M	$-310.82M	$-157.43M	$-64.59M	$-204.52M	$-56.51M	$-284.18M	$-293.87M	$-297.09M	$-407.69M	$-407.69M	$-419.81M	$-317.88M	$-309.08M	$-208.95M	$-209.90M	$-235.74M	$-268.02M	$-226.05M	$-263.72M
High Forecast	$-250.33M	$-253.31M	$-300.57M	$-363.15M	$-363.15M	$-268.02M	$-226.05M	$-263.72M	$-165.50M	$-217.97M	$-328.31M	$-310.82M	$-157.43M	$-64.59M	$-204.52M	$-56.51M	$-284.18M	$-293.87M	$-297.09M	$-407.69M	$-407.69M	$-419.81M	$-317.88M	$-309.08M	$-208.95M	$-209.90M	$-235.74M	$-268.02M	$-226.05M	$-263.72M
Low Forecast	$-250.33M	$-253.31M	$-300.57M	$-363.15M	$-363.15M	$-268.02M	$-226.05M	$-263.72M	$-165.50M	$-217.97M	$-328.31M	$-310.82M	$-157.43M	$-64.59M	$-204.52M	$-56.51M	$-284.18M	$-293.87M	$-297.09M	$-407.69M	$-407.69M	$-419.81M	$-317.88M	$-309.08M	$-208.95M	$-209.90M	$-235.74M	$-268.02M	$-226.05M	$-263.72M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.07%	0.11%	0.06%

Mesoblast's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MESO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Mesoblast SG&A Forecast

	Jun 30	Mar 30	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.65M	$14.28M	$11.76M
Avg Forecast	$115.71M	$96.53M	$24.19M	$22.85M	$22.85M	$12.64M	$12.40M	$20.48M	$44.86M	$12.40M	$20.67M	$13.85M	$104.63M	$172.48M	$92.32M	$239.68M	$75.05M	$53.46M	$24.38M	$12.35M	$12.35M	$9.00M	$24.09M	$22.51M	$40.39M	$33.08M	$14.08M	$12.64M	$12.40M	$18.63M
High Forecast	$115.71M	$96.53M	$24.19M	$22.85M	$22.85M	$12.64M	$12.40M	$20.48M	$44.86M	$12.40M	$20.67M	$13.85M	$104.63M	$172.48M	$92.32M	$239.68M	$75.05M	$53.46M	$24.38M	$12.35M	$12.35M	$9.00M	$24.14M	$22.51M	$40.39M	$33.08M	$14.08M	$12.64M	$12.40M	$18.63M
Low Forecast	$115.71M	$96.53M	$24.19M	$22.85M	$22.85M	$12.64M	$12.40M	$20.48M	$44.86M	$12.40M	$20.67M	$13.85M	$104.63M	$172.48M	$92.32M	$239.68M	$75.05M	$53.46M	$24.38M	$12.35M	$12.35M	$9.00M	$24.04M	$22.51M	$40.39M	$33.08M	$14.08M	$12.64M	$12.40M	$18.63M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00%	1.15%	0.63%

Mesoblast's average Quarter SG&A projection for Jun 23 is $14.08M, based on 1 Wall Street analysts, with a range of $14.08M to $14.08M. The forecast indicates a 11.27% rise compared to MESO last annual SG&A of $12.65M (Mar 23).

Mesoblast EPS Forecast

	Jun 30	Mar 30	Jun 29	Mar 29	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.13	$-0.17	$-0.12
Avg Forecast	$-0.29	$-0.30	$-0.35	$-0.43	$-0.43	$-0.31	$-0.27	$-0.31	$-0.19	$-0.26	$-0.39	$-0.37	$-0.18	$-0.08	$-0.24	$-0.07	$-0.33	$-0.35	$-0.35	$-0.48	$-0.48	$-0.49	$-0.37	$-0.36	$-0.25	$-0.25	$-0.28	$-0.31	$-0.27	$-0.31
High Forecast	$-0.29	$-0.30	$-0.35	$-0.43	$-0.43	$-0.31	$-0.27	$-0.31	$-0.19	$-0.26	$-0.39	$-0.37	$-0.18	$-0.08	$-0.24	$-0.07	$-0.33	$-0.35	$-0.35	$-0.48	$-0.48	$-0.49	$-0.37	$-0.36	$-0.25	$-0.25	$-0.28	$-0.31	$-0.27	$-0.31
Low Forecast	$-0.29	$-0.30	$-0.35	$-0.43	$-0.43	$-0.31	$-0.27	$-0.31	$-0.19	$-0.26	$-0.39	$-0.37	$-0.18	$-0.08	$-0.24	$-0.07	$-0.33	$-0.35	$-0.35	$-0.48	$-0.48	$-0.49	$-0.37	$-0.36	$-0.25	$-0.25	$-0.28	$-0.31	$-0.27	$-0.31
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.41%	0.64%	0.39%

According to undefined Wall Street analysts, Mesoblast's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MESO previous annual EPS of $NaN (undefined).

Mesoblast Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ADTX	Aditxt	$0.32	$160.00	49900.00%	-
VRCA	Verrica Pharmaceuticals	$0.99	$12.00	1112.12%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
INZY	Inozyme Pharma	$2.69	$14.67	445.35%	Buy
FENC	Fennec Pharmaceuticals	$4.72	$15.75	233.69%	Buy
LRMR	Larimar Therapeutics	$6.13	$20.33	231.65%	Buy
ABOS	Acumen Pharmaceuticals	$2.31	$7.00	203.03%	Buy
DAWN	Day One Biopharmaceuticals	$13.34	$38.80	190.85%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
NUVB	Nuvation Bio	$2.70	$6.75	150.00%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
LPCN	Lipocine	$5.00	$10.00	100.00%	Buy
ACHL	Achilles Therapeutics	$1.07	$2.00	86.92%	Buy
CNTB	Connect Biopharma	$0.99	$1.50	51.52%	Buy
HOOK	HOOKIPA Pharma	$2.30	$3.00	30.43%	Buy
ETON	Eton Pharmaceuticals	$10.75	$13.00	20.93%	Buy
MESO	Mesoblast	$10.18	$11.50	12.97%	Buy

MESO Forecast FAQ

Is Mesoblast a good buy?

Yes, according to 11 Wall Street analysts, Mesoblast (MESO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of MESO's total ratings.

What is MESO's price target?

Mesoblast (MESO) average price target is $11.5 with a range of $11 to $12, implying a 12.97% from its last price of $10.18. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Mesoblast stock go up soon?

According to Wall Street analysts' prediction for MESO stock, the company can go up by 12.97% (from the last price of $10.18 to the average price target of $11.5), up by 17.88% based on the highest stock price target, and up by 8.06% based on the lowest stock price target.

Can Mesoblast stock reach $20?

MESO's average twelve months analyst stock price target of $11.5 does not support the claim that Mesoblast can reach $20 in the near future.

What are Mesoblast's analysts' financial forecasts?

Mesoblast's analysts financial forecasts for the fiscal year (Jun 2029) are as follows: average revenue is $13.97M (high $13.97M, low $13.97M), average EBITDA is $-13.974M (high $-13.974M, low $-13.974M), average net income is $-1.295B (high $-1.295B, low $-1.295B), average SG&A $82.54M (high $82.54M, low $82.54M), and average EPS is $-1.521 (high $-1.521, low $-1.521). MESO's analysts financial forecasts for the fiscal year (Jun 2030) are as follows: average revenue is $35.93M (high $35.93M, low $35.93M), average EBITDA is $-35.931M (high $-35.931M, low $-35.931M), average net income is $-504M (high $-504M, low $-504M), average SG&A $212.24M (high $212.24M, low $212.24M), and average EPS is $-0.591 (high $-0.591, low $-0.591).

Did the MESO's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2023), Mesoblast's revenue was $1.94M, missing the average analysts' forecast of $2.14M by -9.38%. The company's EBITDA was $-13.473M, beating the average prediction of $-2.14M by 529.70%. Mesoblast's net income was $-18.6M, missing the average estimation of $-268M by -93.06%. The company's SG&A was $12.65M, beating the average forecast of $12.64M by 0.12%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-0.315 by -58.70%